Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-01-20
2009-06-16
Falk, Ann-Marie (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100
Reexamination Certificate
active
07547681
ABSTRACT:
The invention provides compositions and methods directed to cell surface receptor antigen specific vaccines. More specifically, vaccines are provided that induce or enhance host antibody titers specific for cell surface receptor antigens and that include recombinant expression constructs containing nucleic acids encoding a target cell surface receptor antigen and one or more immune response altering molecules, or the expressed products themselves.
REFERENCES:
patent: 5478556 (1995-12-01), Elliott et al.
patent: 5571711 (1996-11-01), Van der Bruggen et al.
patent: 5596090 (1997-01-01), Hoke et al.
patent: 5683886 (1997-11-01), Van der Bruggen et al.
patent: 5891432 (1999-04-01), Hoo
patent: 6348450 (2002-02-01), Tang et al.
patent: 0668350 (1995-08-01), None
patent: 2241703 (1991-09-01), None
patent: 9-75090 (1991-03-01), None
patent: WO 96/11279 (1996-04-01), None
patent: WO 96/40039 (1996-12-01), None
patent: WO 98/08947 (1998-03-01), None
Babiuk et al. (2003) Induction of immune responses by DNA vaccines in large animals. Vaccine 21: 649-658.
Finn, OJ (2003) Cancer vaccines: Between the idea and the reality. Nature Reviews Immunology 3: 630-641.
Leitner et al. (2000) DNA and RNA-based vaccines: Principles, progress and prospects. Vaccine 18: 765-777.
McCluskie et al. (1999) Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Molecular Medicine 5: 287-300.
Adema et al., “Molecular Characterization of the Melanocyte Lineage-Specific Antigen gp100,”The Journal of Biological Chemistry269(31):20126-20133, 1994.
Banchereau, “Interleukin-4,” in Angus W. Thomson (ed.),The Cytokine Handbook, Academic Press Limited, California, 1991, pp. 119-148.
Bargmann et al., “Multiple Independent Activations of theneuOncogene by a Point Mutation Altering the Transmembrane Domain of p185,”Cell45:649-657, 1986.
Barnd et al., “Specific, Major Histocompatibility Complex-Unrestricted Recognition of Tumor-Associated Mucins by Human Cytotoxic T Cells,”Proc. Natl. Acad. Sci. USA86:7159-7163, 1989.
Baselga et al., “Recombinant Humanized Anti-HER2 Antibody (Herceptin™) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin Against HER2
euOverexpressing Human Breast Cancer Xenografts,”Cancer Research58:2825-2831, 1981.
Bier et al., “Anti-(Epidermal Growth Factor) Receptor Monoclonal Antibodies for the Induction of Antibody-Dependent Cell-Mediated Cytotoxicity Against Squamous Cell Carcinoma Lines of the Head and Neck,”Cancer Immunol. Immunother. 46:167-173, 1998.
Borriello et al., “Differential Expression of Alternate mB7-2 Transcripts,”Journal of Immunology155(12):5490-5497, 1995.
Buonavista et al., “DNA Immunization with a Combination of Rat Neu Antigen, CD86, and 4-IBB Ligand Results in the Generation of HER-2
eu (HER-2) Antigodies in Neu Transgenic Mice,”Cancer Gene Therapy5(6):S2, Abstract No. O-5, 1998.
Conry et al., “Selected strategies to augment polynucleotide immunization,”Gene Therapy3(1):67-74, Jan. 1996.
DeGrado et al., “Sequence and Structural Homologies Among Type I and Type II Interferons,”Nature300(25):379-381, 1982.
Disis et al., “Existent T-Cell and Antibody Immunity of HER-2
eu Protein in Patients with Breast Cancer,”Cancer Research54:16-20, 1991.
Donnelly et al., “DNA Vaccines,”Annual Review of Immunology15(1):617-648, 1997.
Eck et al.,Goodman's and Gilman's the Pharmacological Basis of Therapeutics,McGraw-Hill, New York, 1996 “Gene Based Therapy,” pp. 77-101.
Ehrenfeld and Semler, “Anatomy of the Poliovirus Internal Ribosome Entry Site,”Current Topics in Microbiology and Immunology203:66-83, 1995.
Emtage et al., “Enhanced Interleukin-2 Gene Transfer Immunotherapy of Breast Cancer by Coexpression of B7-1 and B7-2,”Journal of Interferon and Cytokine Research18(11):927-937, 1998.
Farrar and Schreiber, “The Molecular Cell Biology of Interferon-γ and Its Receptor,”Annu. Rev. Immunol. 11:571-611, 1993.
Freeman et al., “B7, A New Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic B Cells,”J. of Immunol. 143(8):2714-1722, 1989.
Freeman et al., “Murine B7-2, and Alternative CTLA4 Counter-Receptor that Costimulates T Cell Proliferation and Interleukin 2 Production,”J. Exp. Med. 178:2185-2192, 1993.
Freeman et al., “Structure, Expression, and T Cell Costimulatory Activity of the Murine Homologue of the Human B Lymphocyte Activation Antigen B7,”J. Exp. Med. 174:625-631, 1991.
Gertsmayer, B. et al., “Costimulation of T Cell Proliferation by a Chimeric B7-2 Antibody Fusion Protein Specifically Targeted to Cells Expressing the Erbb2 Proto-Oncogene,”J. Immunol. 158(10):4585-90, May 1997.
Gold and Freedman, “Demonstration of Tumor-Specific Antigens in Human Colonic Carcinomata by Immunological Tolerance and Absorption Techniques,”J. Exp. Med. 121(3):439-462, plate 35-plate 39, 1965.
Goodwin et al., “Molecular Cloning of a Ligand for the Inducible T Cell Gene 4-1BB: A Member of an Emerging Family of Cytokines with Homology to Tumor Necrosis Factor,”Eur. J. Immunol. 23:2631-2641, 1993.
Gray et al., “Expression of Human Immune Interferon cDNA inE. coliand Monkey Cells,”Nature295:503-508, 1982.
Greene et al., “Covalent Dimerization of CD28/CTLA-4 and Oligomerization of CD80/CD86 Regulate T Cell Costimulatory Interactions,”The Journal of Biological Chemistry271(43):26762-26771, 1996.
Hellström and Hellström, “T Cell Immunity of Tumor Antigens,”Critical Reviews in Immunology18:1-6, 1998.
Hoffman et al., “Antitumor Activity of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and Cisplatin in Ten Human Head and Neck Squamous Cell Carcinoma Lines,”Anticancer Research17:4419-4426, 1997.
June et al., “Role of the CD28 Receptor in T-Cell Activation,”Immunol. Today11:211-216, 1990.
Kawakami et al., “Cloning of the Gene Coding for a Shared Human Melanoma Antigen Recognized by Autologous T Cells Infiltrating Into Tumour,”Proc. Nat. Acad. Sci. USA91:3515-3519, 1994.
Keegan et al., “The Interleukin-4 Receptor: Signal Transduction by a Hematopoietin Receptor,”J. Leukocyt. Biol. 55:272-279, 1994.
Kim et al., “Development of a Multicomponent Candidate Vaccine for HIV-1,”Vaccine15(8):879-883, 1997.
Kwon and Weissman, “cDNA Sequences of Two Inducible T-Cell Genes,”Proc. Nat. Acad. Sci. USA86:1963-1967, 1989.
Li et al., “Costimulation by CD48 and B7-1 Induces Immunity Against Poorly Immunogenic Tumors,”J. Exp. Med. 183:639-644, 1996.
Linsley et al., “CD28 Engagement by B7/BB-1 Induces Transient Down-Regulation of CD28 Synthesis and Prolonged Unresponsiveness to CD28 Signaling,”J. Immunol. 150(8):3161-3169, 1993.
Linsley et al., “Human B7-1 (CD80) and B7-2 (CD86) Bind with Similar Avidites but Distinct Kinetics to CD28 and CTLA-4 Receptors,”Immunity1:793-801, 1994.
Liu, “Vaccine Developments,”Nature Medicine Vaccine Supplement4(5):515-519, 1998.
Melero et al., “Amplification of Tumor Immunity by Gene Transfer of the Co-Stimulatory 4-1BB Ligand: Synergy with the CD28 Co-Stimulatory Pathway,”Eur. J. Immunol28:1116-1121, 1998.
Pardoll, “Cancer Vaccines,”Nature Medicine Vaccine Supplement4(5):525-531, 1998.
Petit et al., “Neutralizing Antibodies Against Epidermal Growth Factor and ErbB-2
euReceptor Tyrosine Kinases Down-Regulate Vascular Endothelial Growth Factor Production by Tumor Cells In Vitro and In Vivo,”American Journal of Pathology151(6):1523-1530, 1997.
Pietras et al., “Antibody to HER-2
euReceptor Blocks DNA Repair After Cisplatin in Human Breast and Ovarian Cancer Cells,”Oncogene9:1829-1838, 1994.
Plowman et al., “Heregulin Induces Tyrosine Phosphoryla
Disis Mary L
Hellstrom Ingegerd
Hellstrom Karl Erik
Scholler Nathalie B
Christensen O'Connor Johnson & Kindness PLLC
Falk Ann-Marie
University of Washington
LandOfFree
Surface receptor antigen vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Surface receptor antigen vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Surface receptor antigen vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4147160